FDA生物标志物鉴定:证据框架

2018-11-21 美国食品和药品监督管理局

美国食品药品监督管理局(FDA或机构)宣布为行业和FDA工作人员提供指南草案,该指南草案的名称为“生物标志物资格:证据框架”。 本指南草案提供了有关一般注意事项的建议,以根据2

中文标题:

FDA生物标志物鉴定:证据框架

发布日期:

2018-11-21

简要介绍:

美国食品药品监督管理局(FDA或机构)宣布为行业和FDA工作人员提供指南草案,该指南草案的名称为“生物标志物资格:证据框架”。 本指南草案提供了有关一般注意事项的建议,以根据2016年12月13日颁布的《 21世纪治愈法案》(《治愈法案》)开发生物标志物进行鉴定时要解决的问题,该法案在《联邦食品,药品和化妆品法案》中增加了新的部分( FD&C法案)。 生物标志物的资格是确定在规定的使用范围内,可以依靠生物标志物在药物开发和法规审查中具有特定的解释和应用。

相关资料下载:
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=63b1e1c00200937f, title=FDA生物标志物鉴定:证据框架, enTitle=, guiderFrom=, authorId=0, author=, summary=美国食品药品监督管理局(FDA或机构)宣布为行业和FDA工作人员提供指南草案,该指南草案的名称为“生物标志物资格:证据框架”。 本指南草案提供了有关一般注意事项的建议,以根据2, cover=, journalId=0, articlesId=null, associationId=486, associationName=美国食品和药品监督管理局, associationIntro=美国食品和药品监督管理局是美国公共卫生及服务部的一个代理商,其由委员会办公室和4个监督核心功能理事机构组成。, copyright=0, guiderPublishedTime=Wed Nov 21 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<p><span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0">美国食品药品监督管理局(FDA或机构)宣布为行业和FDA工作人员提供指南草案,该指南草案的名称为&ldquo;生物标志物资格:证据框架&rdquo;。</span> <span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="1">本指南草案提供了有关一般注意事项的建议,以根据2016年12月13日颁布的《 21世纪治愈法案》(《治愈法案》)开发生物标志物进行鉴定时要解决的问题,该法案在《联邦食品,药品和化妆品法案》中增加了新的部分(</span> <span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="2">FD&C法案)。</span> <span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="3">生物标志物的资格是确定在规定的使用范围内,可以依靠生物标志物在药物开发和法规审查中具有特定的解释和应用。</span></p>, tagList=[TagDto(tagId=1662, tagName=生物标志物)], categoryList=[CategoryDto(categoryId=67, categoryName=研究设计与统计, tenant=100), CategoryDto(categoryId=69, categoryName=检验, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=248, categoryName=真实世界研究, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3170, appHits=45, showAppHits=0, pcHits=711, showPcHits=3125, likes=0, shares=4, comments=5, approvalStatus=1, publishedTime=Mon Nov 16 10:06:49 CST 2020, publishedTimeString=2018-11-21, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Mon Nov 16 10:06:40 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 09:48:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1002001, encodeId=c92d1002001fc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07325555363, createdName=ms2000000104627781, createdTime=Fri Jul 23 14:21:12 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899884, encodeId=540689988453, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ef92129227, createdName=1361fc5d0em, createdTime=Tue Nov 17 15:37:34 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899680, encodeId=b0b6899680e3, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/1c491531b99a4e7a8edb5bd954439ccd/441ae168c0e248ceb0a327e99a8083d4.jpg, createdBy=e7bc5435502, createdName=ms1000001337363233, createdTime=Mon Nov 16 20:09:51 CST 2020, time=2020-11-16, status=1, ipAttribution=)]
    2021-07-23 ms2000000104627781

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1002001, encodeId=c92d1002001fc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07325555363, createdName=ms2000000104627781, createdTime=Fri Jul 23 14:21:12 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899884, encodeId=540689988453, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ef92129227, createdName=1361fc5d0em, createdTime=Tue Nov 17 15:37:34 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899680, encodeId=b0b6899680e3, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/1c491531b99a4e7a8edb5bd954439ccd/441ae168c0e248ceb0a327e99a8083d4.jpg, createdBy=e7bc5435502, createdName=ms1000001337363233, createdTime=Mon Nov 16 20:09:51 CST 2020, time=2020-11-16, status=1, ipAttribution=)]
    2020-11-17 1361fc5d0em

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1002001, encodeId=c92d1002001fc, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07325555363, createdName=ms2000000104627781, createdTime=Fri Jul 23 14:21:12 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899884, encodeId=540689988453, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ef92129227, createdName=1361fc5d0em, createdTime=Tue Nov 17 15:37:34 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899680, encodeId=b0b6899680e3, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/1c491531b99a4e7a8edb5bd954439ccd/441ae168c0e248ceb0a327e99a8083d4.jpg, createdBy=e7bc5435502, createdName=ms1000001337363233, createdTime=Mon Nov 16 20:09:51 CST 2020, time=2020-11-16, status=1, ipAttribution=)]
    2020-11-16 ms1000001337363233

    1

    0